Article Contents ::
- 1 Details About Generic Salt :: Pindolol
- 2 Main Medicine Class:: Beta-adrenergic blocker
- 3
(PIN-doe-lahl)
Visken, Alti-Pindolol, APO-Pindol, Gen-Pindolol, Novo-Pindol, Nu-Pindol
Class: Beta-adrenergic blocker
Action Nonselectively blocks beta receptors, which primarily affect heart (slows rate), vascular musculature (decreases blood pressure) and lungs (reduces function).
Indications Management of mild-to-moderate hypertension.
Contraindications Greater than first-degree heart block; CHF unless secondary to tachyarrhythmia treatable with beta-blockers; overt cardiac failure; sinus bradycardia; cardiogenic shock; hypersensitivity to beta-blockers; bronchial asthma or bronchospasm, including severe COPD.
Route/Dosage
ADULTS: PO 5 mg bid. May be increased by 10 mg q 3 to 4 wk until desired response; maximum dose is 60 mg/day.
Interactions
Clonidine: May enhance or reverse antihypertensive effect; potentially life-threatening situations may occur, especially on withdrawal. Epinephrine: Initial hypertensive episode followed by bradycardia may occur. Ergot alkaloids: Peripheral ischemia, manifested by cold extremities and possible gangrene, may occur. Insulin: Prolonged hypoglycemia with masking of symptoms may occur. Lidocaine: Lidocaine levels may increase, leading to toxicity. Nonsteroidal anti-inflammatory agents: Some agents may impair antihypertensive effect. Prazosin: Orthostatic hypotension may be increased. Theophyllines: Elimination of theophylline may be reduced. Also, effects of both drugs may be reduced by pharmacologic antagonism. Verapamil: Effects of both drugs may be increased.
Lab Test Interferences None well documented.
Adverse Reactions
CV: Bradycardia; hypotension; congestive heart failure; edema; worsening angina. CNS: Depression; visual disturbances; short-term memory loss; dizziness. DERM: Skin rash; increased sensitivity to cold. EENT: Dry eyes; visual disturbances. GI: Nausea; vomiting; diarrhea. GU: Impotence; urinary retention; difficulty with urination. HEMA: Agranulocytosis. HEPA: May increase AST or ALT; rarely increases LDH or alkaline phosphatase. META: May increase or decrease blood glucose, uric acid. RESP: Wheezing; bronchospasm; difficulty breathing (at higher doses).
Precautions
Pregnancy: Category B. Lactation: Excreted in breast milk. Children: Safety and efficacy not established. Anaphylaxis: Deaths have occurred; aggressive therapy may be required. Diabetics: May mask signs and symptoms of hypoglycemia (eg, tachycardia, BP changes). May potentiate insulin-induced hypoglycemia. Peripheral vascular disease: May precipitate or aggravate symptoms of arterial insufficiency. Thyrotoxicosis: May mask clinical signs of developing or continuing hyperthyroidism (eg, tachycardia). Abrupt withdrawal may exacerbate symptoms of hyperthyroidism, including thyroid storm. CHF: Administer cautiously in CHF patients controlled by digitalis and diuretics. Notify physician at first sign or symptom of CHF or unexplained respiratory symptoms in any patient.
Renal/Hepatic function impairment: Dosage may need to be reduced.
PATIENT CARE CONSIDERATIONS
Administration/Storage
Give orally.
Give medication at same time each day.
May be taken without regard to meals.
Store at room temperature and protect from moisture, light, and air.
Assessment/Interventions
Obtain patient history, including drug history and any known allergies.
Assess pulse and BP prior to initiation of therapy.
Monitor BP, apical, and radial pulses, intake and output, daily weight, respiration, and circulation in extremities.
Review baseline serum glucose level, results of liver and renal function studies, and monitor lab data throughout therapy.
Monitor blood glucose closely for diabetic patients.
Notify physician if symptoms of CHF occur (eg, difficulty breathing, cough, or swelling in extremities).
Report bothersome side effects to physician, especially new-onset depression.
Reduce dose gradually upon discontinuation of therapy. Abrupt withdrawal is associated with adverse effects, including precipitation, or worsening of angina.
OVERDOSAGE: SIGNS & SYMPTOMS
Bradycardia, hypotension, seizures, respiratory depression
Patient/Family Education
Teach patient and family technique for measuring BP and pulse rates and to keep written record.
Instruct patient to notify physician if pulse rate is < 50 bpm or systolic BP is < 90 mm Hg.
Warn patient not to engage in activities that require mental alertness until drug effects are apparent because it may cause blurred vision, drowsiness, and dizziness.
Explain that decreased blood supply to extremities may cause patient to be more sensitive to cold temperatures.
Encourage patients with diabetes to monitor blood glucose carefully.
Advise patient to report the following symptoms to physician: Any asthma-like symptoms, cough or nasal stuffiness, skin rash, fever, sore throat, unusual bleeding or bruising.
Instruct patient not to take any otc medications without consulting physician.
Instruct patient to sit or lie down immediately if dizziness or faintness occurs.
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Pindolol
| (PIN-doe-lahl) |
Visken,  Alti-Pindolol, APO-Pindol, Gen-Pindolol, Novo-Pindol, Nu-Pindol |
| Class: Beta-adrenergic blocker |
Action Nonselectively blocks beta receptors, which primarily affect heart (slows rate), vascular musculature (decreases blood pressure) and lungs (reduces function).
Indications Management of mild-to-moderate hypertension.
Contraindications Greater than first-degree heart block; CHF unless secondary to tachyarrhythmia treatable with beta-blockers; overt cardiac failure; sinus bradycardia; cardiogenic shock; hypersensitivity to beta-blockers; bronchial asthma or bronchospasm, including severe COPD.
Route/Dosage
ADULTS: PO 5 mg bid. May be increased by 10 mg q 3 to 4 wk until desired response; maximum dose is 60 mg/day.
Interactions
Clonidine: May enhance or reverse antihypertensive effect; potentially life-threatening situations may occur, especially on withdrawal. Epinephrine: Initial hypertensive episode followed by bradycardia may occur. Ergot alkaloids: Peripheral ischemia, manifested by cold extremities and possible gangrene, may occur. Insulin: Prolonged hypoglycemia with masking of symptoms may occur. Lidocaine: Lidocaine levels may increase, leading to toxicity. Nonsteroidal anti-inflammatory agents: Some agents may impair antihypertensive effect. Prazosin: Orthostatic hypotension may be increased. Theophyllines: Elimination of theophylline may be reduced. Also, effects of both drugs may be reduced by pharmacologic antagonism. Verapamil: Effects of both drugs may be increased.
Lab Test Interferences None well documented.
Adverse Reactions
CV: Bradycardia; hypotension; congestive heart failure; edema; worsening angina. CNS: Depression; visual disturbances; short-term memory loss; dizziness. DERM: Skin rash; increased sensitivity to cold. EENT: Dry eyes; visual disturbances. GI: Nausea; vomiting; diarrhea. GU: Impotence; urinary retention; difficulty with urination. HEMA: Agranulocytosis. HEPA: May increase AST or ALT; rarely increases LDH or alkaline phosphatase. META: May increase or decrease blood glucose, uric acid. RESP: Wheezing; bronchospasm; difficulty breathing (at higher doses).
Precautions
Pregnancy: Category B. Lactation: Excreted in breast milk. Children: Safety and efficacy not established. Anaphylaxis: Deaths have occurred; aggressive therapy may be required. Diabetics: May mask signs and symptoms of hypoglycemia (eg, tachycardia, BP changes). May potentiate insulin-induced hypoglycemia. Peripheral vascular disease: May precipitate or aggravate symptoms of arterial insufficiency. Thyrotoxicosis: May mask clinical signs of developing or continuing hyperthyroidism (eg, tachycardia). Abrupt withdrawal may exacerbate symptoms of hyperthyroidism, including thyroid storm. CHF: Administer cautiously in CHF patients controlled by digitalis and diuretics. Notify physician at first sign or symptom of CHF or unexplained respiratory symptoms in any patient.
Renal/Hepatic function impairment: Dosage may need to be reduced.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Give orally.
- Give medication at same time each day.
- May be taken without regard to meals.
- Store at room temperature and protect from moisture, light, and air.
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Assess pulse and BP prior to initiation of therapy.
- Monitor BP, apical, and radial pulses, intake and output, daily weight, respiration, and circulation in extremities.
- Review baseline serum glucose level, results of liver and renal function studies, and monitor lab data throughout therapy.
- Monitor blood glucose closely for diabetic patients.
- Notify physician if symptoms of CHF occur (eg, difficulty breathing, cough, or swelling in extremities).
- Report bothersome side effects to physician, especially new-onset depression.
- Reduce dose gradually upon discontinuation of therapy. Abrupt withdrawal is associated with adverse effects, including precipitation, or worsening of angina.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Bradycardia, hypotension, seizures, respiratory depression |
|
Patient/Family Education
- Teach patient and family technique for measuring BP and pulse rates and to keep written record.
- Instruct patient to notify physician if pulse rate is < 50 bpm or systolic BP is < 90 mm Hg.
- Warn patient not to engage in activities that require mental alertness until drug effects are apparent because it may cause blurred vision, drowsiness, and dizziness.
- Explain that decreased blood supply to extremities may cause patient to be more sensitive to cold temperatures.
- Encourage patients with diabetes to monitor blood glucose carefully.
- Advise patient to report the following symptoms to physician: Any asthma-like symptoms, cough or nasal stuffiness, skin rash, fever, sore throat, unusual bleeding or bruising.
- Instruct patient not to take any otc medications without consulting physician.
- Instruct patient to sit or lie down immediately if dizziness or faintness occurs.
Drugs Class ::
| (PIN-doe-lahl) |
| Visken, Alti-Pindolol, APO-Pindol, Gen-Pindolol, Novo-Pindol, Nu-Pindol |
| Class: Beta-adrenergic blocker |
Action Nonselectively blocks beta receptors, which primarily affect heart (slows rate), vascular musculature (decreases blood pressure) and lungs (reduces function).
Indications Management of mild-to-moderate hypertension.
Contraindications Greater than first-degree heart block; CHF unless secondary to tachyarrhythmia treatable with beta-blockers; overt cardiac failure; sinus bradycardia; cardiogenic shock; hypersensitivity to beta-blockers; bronchial asthma or bronchospasm, including severe COPD.
Route/Dosage
ADULTS: PO 5 mg bid. May be increased by 10 mg q 3 to 4 wk until desired response; maximum dose is 60 mg/day.
Interactions
Clonidine: May enhance or reverse antihypertensive effect; potentially life-threatening situations may occur, especially on withdrawal. Epinephrine: Initial hypertensive episode followed by bradycardia may occur. Ergot alkaloids: Peripheral ischemia, manifested by cold extremities and possible gangrene, may occur. Insulin: Prolonged hypoglycemia with masking of symptoms may occur. Lidocaine: Lidocaine levels may increase, leading to toxicity. Nonsteroidal anti-inflammatory agents: Some agents may impair antihypertensive effect. Prazosin: Orthostatic hypotension may be increased. Theophyllines: Elimination of theophylline may be reduced. Also, effects of both drugs may be reduced by pharmacologic antagonism. Verapamil: Effects of both drugs may be increased.
Lab Test Interferences None well documented.
Adverse Reactions
CV: Bradycardia; hypotension; congestive heart failure; edema; worsening angina. CNS: Depression; visual disturbances; short-term memory loss; dizziness. DERM: Skin rash; increased sensitivity to cold. EENT: Dry eyes; visual disturbances. GI: Nausea; vomiting; diarrhea. GU: Impotence; urinary retention; difficulty with urination. HEMA: Agranulocytosis. HEPA: May increase AST or ALT; rarely increases LDH or alkaline phosphatase. META: May increase or decrease blood glucose, uric acid. RESP: Wheezing; bronchospasm; difficulty breathing (at higher doses).
Precautions
Pregnancy: Category B. Lactation: Excreted in breast milk. Children: Safety and efficacy not established. Anaphylaxis: Deaths have occurred; aggressive therapy may be required. Diabetics: May mask signs and symptoms of hypoglycemia (eg, tachycardia, BP changes). May potentiate insulin-induced hypoglycemia. Peripheral vascular disease: May precipitate or aggravate symptoms of arterial insufficiency. Thyrotoxicosis: May mask clinical signs of developing or continuing hyperthyroidism (eg, tachycardia). Abrupt withdrawal may exacerbate symptoms of hyperthyroidism, including thyroid storm. CHF: Administer cautiously in CHF patients controlled by digitalis and diuretics. Notify physician at first sign or symptom of CHF or unexplained respiratory symptoms in any patient.
Renal/Hepatic function impairment: Dosage may need to be reduced.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Give orally.
- Give medication at same time each day.
- May be taken without regard to meals.
- Store at room temperature and protect from moisture, light, and air.
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Assess pulse and BP prior to initiation of therapy.
- Monitor BP, apical, and radial pulses, intake and output, daily weight, respiration, and circulation in extremities.
- Review baseline serum glucose level, results of liver and renal function studies, and monitor lab data throughout therapy.
- Monitor blood glucose closely for diabetic patients.
- Notify physician if symptoms of CHF occur (eg, difficulty breathing, cough, or swelling in extremities).
- Report bothersome side effects to physician, especially new-onset depression.
- Reduce dose gradually upon discontinuation of therapy. Abrupt withdrawal is associated with adverse effects, including precipitation, or worsening of angina.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Bradycardia, hypotension, seizures, respiratory depression |
|
Patient/Family Education
- Teach patient and family technique for measuring BP and pulse rates and to keep written record.
- Instruct patient to notify physician if pulse rate is < 50 bpm or systolic BP is < 90 mm Hg.
- Warn patient not to engage in activities that require mental alertness until drug effects are apparent because it may cause blurred vision, drowsiness, and dizziness.
- Explain that decreased blood supply to extremities may cause patient to be more sensitive to cold temperatures.
- Encourage patients with diabetes to monitor blood glucose carefully.
- Advise patient to report the following symptoms to physician: Any asthma-like symptoms, cough or nasal stuffiness, skin rash, fever, sore throat, unusual bleeding or bruising.
- Instruct patient not to take any otc medications without consulting physician.
- Instruct patient to sit or lie down immediately if dizziness or faintness occurs.
Indications for Drugs ::
| (PIN-doe-lahl) |
| Visken, Alti-Pindolol, APO-Pindol, Gen-Pindolol, Novo-Pindol, Nu-Pindol |
| Class: Beta-adrenergic blocker |
Action Nonselectively blocks beta receptors, which primarily affect heart (slows rate), vascular musculature (decreases blood pressure) and lungs (reduces function).
Indications Management of mild-to-moderate hypertension.
Contraindications Greater than first-degree heart block; CHF unless secondary to tachyarrhythmia treatable with beta-blockers; overt cardiac failure; sinus bradycardia; cardiogenic shock; hypersensitivity to beta-blockers; bronchial asthma or bronchospasm, including severe COPD.
Route/Dosage
ADULTS: PO 5 mg bid. May be increased by 10 mg q 3 to 4 wk until desired response; maximum dose is 60 mg/day.
Interactions
Clonidine: May enhance or reverse antihypertensive effect; potentially life-threatening situations may occur, especially on withdrawal. Epinephrine: Initial hypertensive episode followed by bradycardia may occur. Ergot alkaloids: Peripheral ischemia, manifested by cold extremities and possible gangrene, may occur. Insulin: Prolonged hypoglycemia with masking of symptoms may occur. Lidocaine: Lidocaine levels may increase, leading to toxicity. Nonsteroidal anti-inflammatory agents: Some agents may impair antihypertensive effect. Prazosin: Orthostatic hypotension may be increased. Theophyllines: Elimination of theophylline may be reduced. Also, effects of both drugs may be reduced by pharmacologic antagonism. Verapamil: Effects of both drugs may be increased.
Lab Test Interferences None well documented.
Adverse Reactions
CV: Bradycardia; hypotension; congestive heart failure; edema; worsening angina. CNS: Depression; visual disturbances; short-term memory loss; dizziness. DERM: Skin rash; increased sensitivity to cold. EENT: Dry eyes; visual disturbances. GI: Nausea; vomiting; diarrhea. GU: Impotence; urinary retention; difficulty with urination. HEMA: Agranulocytosis. HEPA: May increase AST or ALT; rarely increases LDH or alkaline phosphatase. META: May increase or decrease blood glucose, uric acid. RESP: Wheezing; bronchospasm; difficulty breathing (at higher doses).
Precautions
Pregnancy: Category B. Lactation: Excreted in breast milk. Children: Safety and efficacy not established. Anaphylaxis: Deaths have occurred; aggressive therapy may be required. Diabetics: May mask signs and symptoms of hypoglycemia (eg, tachycardia, BP changes). May potentiate insulin-induced hypoglycemia. Peripheral vascular disease: May precipitate or aggravate symptoms of arterial insufficiency. Thyrotoxicosis: May mask clinical signs of developing or continuing hyperthyroidism (eg, tachycardia). Abrupt withdrawal may exacerbate symptoms of hyperthyroidism, including thyroid storm. CHF: Administer cautiously in CHF patients controlled by digitalis and diuretics. Notify physician at first sign or symptom of CHF or unexplained respiratory symptoms in any patient.
Renal/Hepatic function impairment: Dosage may need to be reduced.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Give orally.
- Give medication at same time each day.
- May be taken without regard to meals.
- Store at room temperature and protect from moisture, light, and air.
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Assess pulse and BP prior to initiation of therapy.
- Monitor BP, apical, and radial pulses, intake and output, daily weight, respiration, and circulation in extremities.
- Review baseline serum glucose level, results of liver and renal function studies, and monitor lab data throughout therapy.
- Monitor blood glucose closely for diabetic patients.
- Notify physician if symptoms of CHF occur (eg, difficulty breathing, cough, or swelling in extremities).
- Report bothersome side effects to physician, especially new-onset depression.
- Reduce dose gradually upon discontinuation of therapy. Abrupt withdrawal is associated with adverse effects, including precipitation, or worsening of angina.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Bradycardia, hypotension, seizures, respiratory depression |
|
Patient/Family Education
- Teach patient and family technique for measuring BP and pulse rates and to keep written record.
- Instruct patient to notify physician if pulse rate is < 50 bpm or systolic BP is < 90 mm Hg.
- Warn patient not to engage in activities that require mental alertness until drug effects are apparent because it may cause blurred vision, drowsiness, and dizziness.
- Explain that decreased blood supply to extremities may cause patient to be more sensitive to cold temperatures.
- Encourage patients with diabetes to monitor blood glucose carefully.
- Advise patient to report the following symptoms to physician: Any asthma-like symptoms, cough or nasal stuffiness, skin rash, fever, sore throat, unusual bleeding or bruising.
- Instruct patient not to take any otc medications without consulting physician.
- Instruct patient to sit or lie down immediately if dizziness or faintness occurs.
Drug Dose ::
| (PIN-doe-lahl) |
| Visken, Alti-Pindolol, APO-Pindol, Gen-Pindolol, Novo-Pindol, Nu-Pindol |
| Class: Beta-adrenergic blocker |
Action Nonselectively blocks beta receptors, which primarily affect heart (slows rate), vascular musculature (decreases blood pressure) and lungs (reduces function).
Indications Management of mild-to-moderate hypertension.
Contraindications Greater than first-degree heart block; CHF unless secondary to tachyarrhythmia treatable with beta-blockers; overt cardiac failure; sinus bradycardia; cardiogenic shock; hypersensitivity to beta-blockers; bronchial asthma or bronchospasm, including severe COPD.
Route/Dosage
ADULTS: PO 5 mg bid. May be increased by 10 mg q 3 to 4 wk until desired response; maximum dose is 60 mg/day.
Interactions
Clonidine: May enhance or reverse antihypertensive effect; potentially life-threatening situations may occur, especially on withdrawal. Epinephrine: Initial hypertensive episode followed by bradycardia may occur. Ergot alkaloids: Peripheral ischemia, manifested by cold extremities and possible gangrene, may occur. Insulin: Prolonged hypoglycemia with masking of symptoms may occur. Lidocaine: Lidocaine levels may increase, leading to toxicity. Nonsteroidal anti-inflammatory agents: Some agents may impair antihypertensive effect. Prazosin: Orthostatic hypotension may be increased. Theophyllines: Elimination of theophylline may be reduced. Also, effects of both drugs may be reduced by pharmacologic antagonism. Verapamil: Effects of both drugs may be increased.
Lab Test Interferences None well documented.
Adverse Reactions
CV: Bradycardia; hypotension; congestive heart failure; edema; worsening angina. CNS: Depression; visual disturbances; short-term memory loss; dizziness. DERM: Skin rash; increased sensitivity to cold. EENT: Dry eyes; visual disturbances. GI: Nausea; vomiting; diarrhea. GU: Impotence; urinary retention; difficulty with urination. HEMA: Agranulocytosis. HEPA: May increase AST or ALT; rarely increases LDH or alkaline phosphatase. META: May increase or decrease blood glucose, uric acid. RESP: Wheezing; bronchospasm; difficulty breathing (at higher doses).
Precautions
Pregnancy: Category B. Lactation: Excreted in breast milk. Children: Safety and efficacy not established. Anaphylaxis: Deaths have occurred; aggressive therapy may be required. Diabetics: May mask signs and symptoms of hypoglycemia (eg, tachycardia, BP changes). May potentiate insulin-induced hypoglycemia. Peripheral vascular disease: May precipitate or aggravate symptoms of arterial insufficiency. Thyrotoxicosis: May mask clinical signs of developing or continuing hyperthyroidism (eg, tachycardia). Abrupt withdrawal may exacerbate symptoms of hyperthyroidism, including thyroid storm. CHF: Administer cautiously in CHF patients controlled by digitalis and diuretics. Notify physician at first sign or symptom of CHF or unexplained respiratory symptoms in any patient.
Renal/Hepatic function impairment: Dosage may need to be reduced.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Give orally.
- Give medication at same time each day.
- May be taken without regard to meals.
- Store at room temperature and protect from moisture, light, and air.
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Assess pulse and BP prior to initiation of therapy.
- Monitor BP, apical, and radial pulses, intake and output, daily weight, respiration, and circulation in extremities.
- Review baseline serum glucose level, results of liver and renal function studies, and monitor lab data throughout therapy.
- Monitor blood glucose closely for diabetic patients.
- Notify physician if symptoms of CHF occur (eg, difficulty breathing, cough, or swelling in extremities).
- Report bothersome side effects to physician, especially new-onset depression.
- Reduce dose gradually upon discontinuation of therapy. Abrupt withdrawal is associated with adverse effects, including precipitation, or worsening of angina.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Bradycardia, hypotension, seizures, respiratory depression |
|
Patient/Family Education
- Teach patient and family technique for measuring BP and pulse rates and to keep written record.
- Instruct patient to notify physician if pulse rate is < 50 bpm or systolic BP is < 90 mm Hg.
- Warn patient not to engage in activities that require mental alertness until drug effects are apparent because it may cause blurred vision, drowsiness, and dizziness.
- Explain that decreased blood supply to extremities may cause patient to be more sensitive to cold temperatures.
- Encourage patients with diabetes to monitor blood glucose carefully.
- Advise patient to report the following symptoms to physician: Any asthma-like symptoms, cough or nasal stuffiness, skin rash, fever, sore throat, unusual bleeding or bruising.
- Instruct patient not to take any otc medications without consulting physician.
- Instruct patient to sit or lie down immediately if dizziness or faintness occurs.
Contraindication ::
| (PIN-doe-lahl) |
| Visken, Alti-Pindolol, APO-Pindol, Gen-Pindolol, Novo-Pindol, Nu-Pindol |
| Class: Beta-adrenergic blocker |
Action Nonselectively blocks beta receptors, which primarily affect heart (slows rate), vascular musculature (decreases blood pressure) and lungs (reduces function).
Indications Management of mild-to-moderate hypertension.
Contraindications Greater than first-degree heart block; CHF unless secondary to tachyarrhythmia treatable with beta-blockers; overt cardiac failure; sinus bradycardia; cardiogenic shock; hypersensitivity to beta-blockers; bronchial asthma or bronchospasm, including severe COPD.
Route/Dosage
ADULTS: PO 5 mg bid. May be increased by 10 mg q 3 to 4 wk until desired response; maximum dose is 60 mg/day.
Interactions
Clonidine: May enhance or reverse antihypertensive effect; potentially life-threatening situations may occur, especially on withdrawal. Epinephrine: Initial hypertensive episode followed by bradycardia may occur. Ergot alkaloids: Peripheral ischemia, manifested by cold extremities and possible gangrene, may occur. Insulin: Prolonged hypoglycemia with masking of symptoms may occur. Lidocaine: Lidocaine levels may increase, leading to toxicity. Nonsteroidal anti-inflammatory agents: Some agents may impair antihypertensive effect. Prazosin: Orthostatic hypotension may be increased. Theophyllines: Elimination of theophylline may be reduced. Also, effects of both drugs may be reduced by pharmacologic antagonism. Verapamil: Effects of both drugs may be increased.
Lab Test Interferences None well documented.
Adverse Reactions
CV: Bradycardia; hypotension; congestive heart failure; edema; worsening angina. CNS: Depression; visual disturbances; short-term memory loss; dizziness. DERM: Skin rash; increased sensitivity to cold. EENT: Dry eyes; visual disturbances. GI: Nausea; vomiting; diarrhea. GU: Impotence; urinary retention; difficulty with urination. HEMA: Agranulocytosis. HEPA: May increase AST or ALT; rarely increases LDH or alkaline phosphatase. META: May increase or decrease blood glucose, uric acid. RESP: Wheezing; bronchospasm; difficulty breathing (at higher doses).
Precautions
Pregnancy: Category B. Lactation: Excreted in breast milk. Children: Safety and efficacy not established. Anaphylaxis: Deaths have occurred; aggressive therapy may be required. Diabetics: May mask signs and symptoms of hypoglycemia (eg, tachycardia, BP changes). May potentiate insulin-induced hypoglycemia. Peripheral vascular disease: May precipitate or aggravate symptoms of arterial insufficiency. Thyrotoxicosis: May mask clinical signs of developing or continuing hyperthyroidism (eg, tachycardia). Abrupt withdrawal may exacerbate symptoms of hyperthyroidism, including thyroid storm. CHF: Administer cautiously in CHF patients controlled by digitalis and diuretics. Notify physician at first sign or symptom of CHF or unexplained respiratory symptoms in any patient.
Renal/Hepatic function impairment: Dosage may need to be reduced.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Give orally.
- Give medication at same time each day.
- May be taken without regard to meals.
- Store at room temperature and protect from moisture, light, and air.
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Assess pulse and BP prior to initiation of therapy.
- Monitor BP, apical, and radial pulses, intake and output, daily weight, respiration, and circulation in extremities.
- Review baseline serum glucose level, results of liver and renal function studies, and monitor lab data throughout therapy.
- Monitor blood glucose closely for diabetic patients.
- Notify physician if symptoms of CHF occur (eg, difficulty breathing, cough, or swelling in extremities).
- Report bothersome side effects to physician, especially new-onset depression.
- Reduce dose gradually upon discontinuation of therapy. Abrupt withdrawal is associated with adverse effects, including precipitation, or worsening of angina.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Bradycardia, hypotension, seizures, respiratory depression |
|
Patient/Family Education
- Teach patient and family technique for measuring BP and pulse rates and to keep written record.
- Instruct patient to notify physician if pulse rate is < 50 bpm or systolic BP is < 90 mm Hg.
- Warn patient not to engage in activities that require mental alertness until drug effects are apparent because it may cause blurred vision, drowsiness, and dizziness.
- Explain that decreased blood supply to extremities may cause patient to be more sensitive to cold temperatures.
- Encourage patients with diabetes to monitor blood glucose carefully.
- Advise patient to report the following symptoms to physician: Any asthma-like symptoms, cough or nasal stuffiness, skin rash, fever, sore throat, unusual bleeding or bruising.
- Instruct patient not to take any otc medications without consulting physician.
- Instruct patient to sit or lie down immediately if dizziness or faintness occurs.
Drug Precautions ::
| (PIN-doe-lahl) |
| Visken, Alti-Pindolol, APO-Pindol, Gen-Pindolol, Novo-Pindol, Nu-Pindol |
| Class: Beta-adrenergic blocker |
Action Nonselectively blocks beta receptors, which primarily affect heart (slows rate), vascular musculature (decreases blood pressure) and lungs (reduces function).
Indications Management of mild-to-moderate hypertension.
Contraindications Greater than first-degree heart block; CHF unless secondary to tachyarrhythmia treatable with beta-blockers; overt cardiac failure; sinus bradycardia; cardiogenic shock; hypersensitivity to beta-blockers; bronchial asthma or bronchospasm, including severe COPD.
Route/Dosage
ADULTS: PO 5 mg bid. May be increased by 10 mg q 3 to 4 wk until desired response; maximum dose is 60 mg/day.
Interactions
Clonidine: May enhance or reverse antihypertensive effect; potentially life-threatening situations may occur, especially on withdrawal. Epinephrine: Initial hypertensive episode followed by bradycardia may occur. Ergot alkaloids: Peripheral ischemia, manifested by cold extremities and possible gangrene, may occur. Insulin: Prolonged hypoglycemia with masking of symptoms may occur. Lidocaine: Lidocaine levels may increase, leading to toxicity. Nonsteroidal anti-inflammatory agents: Some agents may impair antihypertensive effect. Prazosin: Orthostatic hypotension may be increased. Theophyllines: Elimination of theophylline may be reduced. Also, effects of both drugs may be reduced by pharmacologic antagonism. Verapamil: Effects of both drugs may be increased.
Lab Test Interferences None well documented.
Adverse Reactions
CV: Bradycardia; hypotension; congestive heart failure; edema; worsening angina. CNS: Depression; visual disturbances; short-term memory loss; dizziness. DERM: Skin rash; increased sensitivity to cold. EENT: Dry eyes; visual disturbances. GI: Nausea; vomiting; diarrhea. GU: Impotence; urinary retention; difficulty with urination. HEMA: Agranulocytosis. HEPA: May increase AST or ALT; rarely increases LDH or alkaline phosphatase. META: May increase or decrease blood glucose, uric acid. RESP: Wheezing; bronchospasm; difficulty breathing (at higher doses).
Precautions
Pregnancy: Category B. Lactation: Excreted in breast milk. Children: Safety and efficacy not established. Anaphylaxis: Deaths have occurred; aggressive therapy may be required. Diabetics: May mask signs and symptoms of hypoglycemia (eg, tachycardia, BP changes). May potentiate insulin-induced hypoglycemia. Peripheral vascular disease: May precipitate or aggravate symptoms of arterial insufficiency. Thyrotoxicosis: May mask clinical signs of developing or continuing hyperthyroidism (eg, tachycardia). Abrupt withdrawal may exacerbate symptoms of hyperthyroidism, including thyroid storm. CHF: Administer cautiously in CHF patients controlled by digitalis and diuretics. Notify physician at first sign or symptom of CHF or unexplained respiratory symptoms in any patient.
Renal/Hepatic function impairment: Dosage may need to be reduced.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Give orally.
- Give medication at same time each day.
- May be taken without regard to meals.
- Store at room temperature and protect from moisture, light, and air.
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Assess pulse and BP prior to initiation of therapy.
- Monitor BP, apical, and radial pulses, intake and output, daily weight, respiration, and circulation in extremities.
- Review baseline serum glucose level, results of liver and renal function studies, and monitor lab data throughout therapy.
- Monitor blood glucose closely for diabetic patients.
- Notify physician if symptoms of CHF occur (eg, difficulty breathing, cough, or swelling in extremities).
- Report bothersome side effects to physician, especially new-onset depression.
- Reduce dose gradually upon discontinuation of therapy. Abrupt withdrawal is associated with adverse effects, including precipitation, or worsening of angina.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Bradycardia, hypotension, seizures, respiratory depression |
|
Patient/Family Education
- Teach patient and family technique for measuring BP and pulse rates and to keep written record.
- Instruct patient to notify physician if pulse rate is < 50 bpm or systolic BP is < 90 mm Hg.
- Warn patient not to engage in activities that require mental alertness until drug effects are apparent because it may cause blurred vision, drowsiness, and dizziness.
- Explain that decreased blood supply to extremities may cause patient to be more sensitive to cold temperatures.
- Encourage patients with diabetes to monitor blood glucose carefully.
- Advise patient to report the following symptoms to physician: Any asthma-like symptoms, cough or nasal stuffiness, skin rash, fever, sore throat, unusual bleeding or bruising.
- Instruct patient not to take any otc medications without consulting physician.
- Instruct patient to sit or lie down immediately if dizziness or faintness occurs.
Drug Side Effects ::
| (PIN-doe-lahl) |
| Visken, Alti-Pindolol, APO-Pindol, Gen-Pindolol, Novo-Pindol, Nu-Pindol |
| Class: Beta-adrenergic blocker |
Action Nonselectively blocks beta receptors, which primarily affect heart (slows rate), vascular musculature (decreases blood pressure) and lungs (reduces function).
Indications Management of mild-to-moderate hypertension.
Contraindications Greater than first-degree heart block; CHF unless secondary to tachyarrhythmia treatable with beta-blockers; overt cardiac failure; sinus bradycardia; cardiogenic shock; hypersensitivity to beta-blockers; bronchial asthma or bronchospasm, including severe COPD.
Route/Dosage
ADULTS: PO 5 mg bid. May be increased by 10 mg q 3 to 4 wk until desired response; maximum dose is 60 mg/day.
Interactions
Clonidine: May enhance or reverse antihypertensive effect; potentially life-threatening situations may occur, especially on withdrawal. Epinephrine: Initial hypertensive episode followed by bradycardia may occur. Ergot alkaloids: Peripheral ischemia, manifested by cold extremities and possible gangrene, may occur. Insulin: Prolonged hypoglycemia with masking of symptoms may occur. Lidocaine: Lidocaine levels may increase, leading to toxicity. Nonsteroidal anti-inflammatory agents: Some agents may impair antihypertensive effect. Prazosin: Orthostatic hypotension may be increased. Theophyllines: Elimination of theophylline may be reduced. Also, effects of both drugs may be reduced by pharmacologic antagonism. Verapamil: Effects of both drugs may be increased.
Lab Test Interferences None well documented.
Adverse Reactions
CV: Bradycardia; hypotension; congestive heart failure; edema; worsening angina. CNS: Depression; visual disturbances; short-term memory loss; dizziness. DERM: Skin rash; increased sensitivity to cold. EENT: Dry eyes; visual disturbances. GI: Nausea; vomiting; diarrhea. GU: Impotence; urinary retention; difficulty with urination. HEMA: Agranulocytosis. HEPA: May increase AST or ALT; rarely increases LDH or alkaline phosphatase. META: May increase or decrease blood glucose, uric acid. RESP: Wheezing; bronchospasm; difficulty breathing (at higher doses).
Precautions
Pregnancy: Category B. Lactation: Excreted in breast milk. Children: Safety and efficacy not established. Anaphylaxis: Deaths have occurred; aggressive therapy may be required. Diabetics: May mask signs and symptoms of hypoglycemia (eg, tachycardia, BP changes). May potentiate insulin-induced hypoglycemia. Peripheral vascular disease: May precipitate or aggravate symptoms of arterial insufficiency. Thyrotoxicosis: May mask clinical signs of developing or continuing hyperthyroidism (eg, tachycardia). Abrupt withdrawal may exacerbate symptoms of hyperthyroidism, including thyroid storm. CHF: Administer cautiously in CHF patients controlled by digitalis and diuretics. Notify physician at first sign or symptom of CHF or unexplained respiratory symptoms in any patient.
Renal/Hepatic function impairment: Dosage may need to be reduced.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Give orally.
- Give medication at same time each day.
- May be taken without regard to meals.
- Store at room temperature and protect from moisture, light, and air.
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Assess pulse and BP prior to initiation of therapy.
- Monitor BP, apical, and radial pulses, intake and output, daily weight, respiration, and circulation in extremities.
- Review baseline serum glucose level, results of liver and renal function studies, and monitor lab data throughout therapy.
- Monitor blood glucose closely for diabetic patients.
- Notify physician if symptoms of CHF occur (eg, difficulty breathing, cough, or swelling in extremities).
- Report bothersome side effects to physician, especially new-onset depression.
- Reduce dose gradually upon discontinuation of therapy. Abrupt withdrawal is associated with adverse effects, including precipitation, or worsening of angina.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Bradycardia, hypotension, seizures, respiratory depression |
|
Patient/Family Education
- Teach patient and family technique for measuring BP and pulse rates and to keep written record.
- Instruct patient to notify physician if pulse rate is < 50 bpm or systolic BP is < 90 mm Hg.
- Warn patient not to engage in activities that require mental alertness until drug effects are apparent because it may cause blurred vision, drowsiness, and dizziness.
- Explain that decreased blood supply to extremities may cause patient to be more sensitive to cold temperatures.
- Encourage patients with diabetes to monitor blood glucose carefully.
- Advise patient to report the following symptoms to physician: Any asthma-like symptoms, cough or nasal stuffiness, skin rash, fever, sore throat, unusual bleeding or bruising.
- Instruct patient not to take any otc medications without consulting physician.
- Instruct patient to sit or lie down immediately if dizziness or faintness occurs.
Drug Mode of Action ::
| (PIN-doe-lahl) |
| Visken, Alti-Pindolol, APO-Pindol, Gen-Pindolol, Novo-Pindol, Nu-Pindol |
| Class: Beta-adrenergic blocker |
Action Nonselectively blocks beta receptors, which primarily affect heart (slows rate), vascular musculature (decreases blood pressure) and lungs (reduces function).
Indications Management of mild-to-moderate hypertension.
